EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study.
biomarkers
cardiovascular disease
chronic kidney disease
data linkage
diabetes mellitus
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
14 Apr 2020
14 Apr 2020
Historique:
received:
28
07
2019
accepted:
07
01
2020
revised:
06
12
2019
entrez:
15
4
2020
pubmed:
15
4
2020
medline:
15
4
2020
Statut:
epublish
Résumé
Chronic kidney disease (CKD) and diabetes are the major causes of death and disability worldwide. They are associated with high health service utilization persisting over many years. Their slow progression and wide clinical variation make them eminently suitable for study in population-based cohorts. However, current understanding of their prevalence, incidence, and progression is largely based on studies conducted in clinical populations. This study aims to establish a novel link between an existing population-based cohort (the 45 and Up Study) and routinely collected laboratory and administrative data to facilitate research across the full disease spectrum of CKD and diabetes. In the EXTEND45 Study (EXamining OuTcomEs in chroNic Disease in the 45 and Up Study), baseline questionnaire responses of over 260,000 participants of the 45 and Up Study aged ≥45 years living in New South Wales (NSW), collected between January 2006 and December 2009, are linked to data from laboratory service providers as well as national- and state-based administrative datasets via probabilistic linkage. Routinely collected data were obtained for participants who could be linked between January 2005 and July 2013. Laboratory data will enable the identification of early cases of chronic disease and the assessment of clinically relevant biochemical targets during the disease course. Health administrative datasets will allow for the examination of health service use, pharmacological management, and clinical outcomes. The study received ethics approval from the NSW Population and Health Services Research Ethics Committee in February 2014. Data linkage for 267,153 of the 45 and Up Study participants was completed in June 2016, with congruent linkage achieved for 265,086 (99.23%) individuals. To date, the CKD and diabetes cohorts have been identified (published elsewhere), and a diverse portfolio of research projects relating to disease burden, risk factors, health outcomes, and health service utilization is in development. The EXTEND45 Study represents an unparalleled opportunity to perform extensive research into diseases of considerable public health and clinical importance. Strengths include the population-based nature of the cohort and the availability of longitudinal information on the complete disease pathway for affected individuals. RR1-10.2196/15646.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic kidney disease (CKD) and diabetes are the major causes of death and disability worldwide. They are associated with high health service utilization persisting over many years. Their slow progression and wide clinical variation make them eminently suitable for study in population-based cohorts. However, current understanding of their prevalence, incidence, and progression is largely based on studies conducted in clinical populations.
OBJECTIVE
OBJECTIVE
This study aims to establish a novel link between an existing population-based cohort (the 45 and Up Study) and routinely collected laboratory and administrative data to facilitate research across the full disease spectrum of CKD and diabetes.
METHODS
METHODS
In the EXTEND45 Study (EXamining OuTcomEs in chroNic Disease in the 45 and Up Study), baseline questionnaire responses of over 260,000 participants of the 45 and Up Study aged ≥45 years living in New South Wales (NSW), collected between January 2006 and December 2009, are linked to data from laboratory service providers as well as national- and state-based administrative datasets via probabilistic linkage. Routinely collected data were obtained for participants who could be linked between January 2005 and July 2013. Laboratory data will enable the identification of early cases of chronic disease and the assessment of clinically relevant biochemical targets during the disease course. Health administrative datasets will allow for the examination of health service use, pharmacological management, and clinical outcomes.
RESULTS
RESULTS
The study received ethics approval from the NSW Population and Health Services Research Ethics Committee in February 2014. Data linkage for 267,153 of the 45 and Up Study participants was completed in June 2016, with congruent linkage achieved for 265,086 (99.23%) individuals. To date, the CKD and diabetes cohorts have been identified (published elsewhere), and a diverse portfolio of research projects relating to disease burden, risk factors, health outcomes, and health service utilization is in development.
CONCLUSIONS
CONCLUSIONS
The EXTEND45 Study represents an unparalleled opportunity to perform extensive research into diseases of considerable public health and clinical importance. Strengths include the population-based nature of the cohort and the availability of longitudinal information on the complete disease pathway for affected individuals.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
RR1-10.2196/15646.
Identifiants
pubmed: 32285803
pii: v9i4e15646
doi: 10.2196/15646
pmc: PMC7189250
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15646Informations de copyright
©Celine Foote, Carinna Hockham, Louisa Sukkar, Anna Campain, Amy Kang, Tamara Young, Alan Cass, Clara K Chow, Elizabeth Comino, Martin Gallagher, Stephen Jan, John Knight, Bette Liu, Martin McNamara, David Peiris, Carol Pollock, David Sullivan, Germaine Wong, Sophia Zoungas, Kris Rogers, Min Jun, Meg Jardine. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 14.04.2020.
Références
Nutr Metab Cardiovasc Dis. 2010 Jul;20(6):474-80
pubmed: 20621459
Lancet. 2013 Jul 27;382(9889):339-52
pubmed: 23727170
Lancet. 2012 Sep 1;380(9844):807-14
pubmed: 22717317
Qual Life Res. 2004 Mar;13(2):283-98
pubmed: 15085901
Environ Geochem Health. 2013 Aug;35(4):439-54
pubmed: 23475496
Ann Intern Med. 2006 Aug 15;145(4):237-46
pubmed: 16908914
Clin J Am Soc Nephrol. 2013 Aug;8(8):1327-35
pubmed: 23833317
Endocrine. 2017 Jan;55(1):66-76
pubmed: 27477292
J Am Heart Assoc. 2016 May 23;5(5):
pubmed: 27217497
Int J Epidemiol. 2008 Oct;37(5):941-7
pubmed: 17881411
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Eur J Surg Oncol. 2010 Aug;36(8):709-17
pubmed: 20542657
BMC Nephrol. 2009 Oct 19;10:30
pubmed: 19840369
BMC Med Res Methodol. 2010 Apr 01;10:26
pubmed: 20356408
Front Immunol. 2015 Jul 08;6:340
pubmed: 26217336
Am J Kidney Dis. 2010 Mar;55(3 Suppl 2):S23-33
pubmed: 20172445
JAMA. 2007 May 2;297(17):1892-900
pubmed: 17473299
Medicine (Baltimore). 2016 Jun;95(25):e3882
pubmed: 27336875
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Diabetes Care. 2014;37(1):277-85
pubmed: 23920086
Aust N Z J Public Health. 2005 Oct;29(5):422-8
pubmed: 16255443